newsfilter
← Latest News
Business Wire·

GoodRx Reports Second Quarter 2026 Results

Pharma Direct and Subscription Revenue Increased 76% and 39%, Respectively, Year-Over-Year Company Raises Full-Year 2026 Revenue and Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we,"